However, shH19 treatment could significantly reverse the abnormal expressions of α-SMA, SM22α, MMP-2, and MMP-9 in AD group (P<0.01, Figure 4D–F, Supplementary Figure S4). The gene discussed is ACTA1; the disease is Alzheimer disease.